Clinical trials: System Lupus Erythematosus
Lupus Nephritis
Urinary T Cell Biomarker for Prediction in Lupus Nephritis
Urinary T-lymphocytes may be predictive for clinical outcome in patients with lupus nephritis. The investigators hypothesize that the amount of CD4+ effector/memory T-cells in urine at time of diagnosis predicts the outcome of…
- Trial name
- NCT04320797
- Testing
- Flow cytometry analysis of urine samples
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Charite University, Berlin, Germany
Atherosclerosis
Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus
The aim of this study is to evaluate subclinical atherosclerosis in children and adolescents with juvenile SLE by measuring carotid intima-media thickness (CIMT), and to determine its associations with traditional cardiovascular…
- Trial name
- NCT07545408
- Volunteers
- 70 people
- Sponsor
- Assiut University
Lupus Nephritis (LN)
The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Systemic lupus erythematosis (SLE) is a chronic, most probably auto-immune multisystem disease marked by relapsing-remitting course and the formation of a range of autoantibodies.
- Trial name
- NCT07700940
- Testing
- Empagliflozin (25 Mg Tab) along with standard medical therapy
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Ahmed Yehia Ismail
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- NCT07104721
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
The purpose of this study is to obtain skin, blood, and urine samples from patients with active cutaneous lupus lesions and from healthy participants.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
- Trial name
- NCT02034344
- Testing
- Skin biopsy, Blood collection, Urine collection
- Where
- 21 sites in United States, Germany and 4 more
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Systemic Lupus Erythematosus
A Model About the Response of Belimumab in SLE
A prospective, single-center cohort study aims to determine a predictive model of the response of belimumab at Week 48.
- Trial name
- MRBS (NCT04893161)
- Testing
- Belimumab
- Volunteers
- 72 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Systemic Lupus Erythematosus (SLE)
A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients with Systemic Lupus…
- Trial name
- NCT05140824
- Testing
- TJ202 injection
- Where
- 2 sites in China
- Volunteers
- 1 people
- Sponsor
- TJ Biopharma Co., Ltd.
Systemic Lupus Erythematosus
Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects
This is a Phase 1 study to investigate the safety, tolerability and pharmacokinetics (PK) of KPG-818 in healthy male and female participants and the effect of food on the PK of KPG-818.
- Trial name
- NCT03949426
- Testing
- KPG-818
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kangpu Biopharmaceuticals, Ltd.
Lupus Nephritis, Belimumab
Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.
The objective of this observational study is to compare the efficacy and safety of telitacicept and belimumab in the treatment of lupus nephritis in patients aged 18-65 years with lupus nephritis.
- Trial name
- NCT07031674
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Yipeng Liu
Systemic Lupus Erythematosus (SLE)
Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients
The study aimed to evaluate the efficacy of seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and…
- Trial name
- NCT06659068
- Testing
- Seluang fish oil (Rasbora argyrotaenia) and synbiotic
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Sriwijaya
Systemic Lupus Erythematosus (SLE)
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus.
- Trial name
- NCT07031713
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Autoimmune Diseases, Non-small Cell Lung Cancer
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease.
- Conditions
- Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis
- Trial name
- NCT03656627
- Testing
- Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Systemic Lupus Erythematosus (SLE)
Descartes-08 for Patients With Systemic Lupus Erythematosus
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
- Trial name
- SLE-001 (NCT06038474)
- Testing
- Descartes-08
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cartesian Therapeutics
Systemic Lupus Erythematosus
Study of Epratuzumab in Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.
- Trial name
- NCT00111306
- Testing
- epratuzumab
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 510 people
- Sponsor
- UCB Pharma
Lupus Nephritis (LN)
High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)
The goal of this observational study is to learn about the long-term renal and patient's survival of lupus nephritis (LN) patients in China.
- Trial name
- HOPE (NCT06682507)
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Safety, Effective
Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
This is an open, Phase I, investigator-initiated study (IIT) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with moderate or severe active SLE.
- Trial name
- NCT06310811
- Testing
- RD06-04 Cells injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Immune System Diseases, Autoimmune Diseases
Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
To evaluate safety, tolerability, pharmacokinetics and immunogenicity of CDP7657
- Conditions
- Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases
- Trial name
- NCT01093911
- Testing
- CDP7657
- Where
- 8 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus
Development of a Dietary Intervention Model Based on Genetic Data as an Implementation of a Healthy Lifestyle in the Management of Systemic Lupus Erythematosus Patients
The goal of this clinical trial is to learn if dietary intervention based on genetic data benefits in the management of systemic lupus erythematosus patients. It will also learn about the safety of this intervention.
- Trial name
- NCT07183007
- Testing
- Low gluten diet
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Universitas Indonesia
Childhood-onset Systemic Lupus Erythematosus
Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
This prospective observational study aims to characterize the peripheral immune landscape of pediatric patients with childhood-onset systemic lupus erythematosus ( cSLE) who are receiving CD3×CD19 bispecific T-cell engager (BiTE)…
- Trial name
- BiTE-cSLE-IP (NCT07352332)
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
- Trial name
- NCT06625671
- Testing
- DB-2304, Prednisone
- Where
- 7 sites in United States, Australia
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- DualityBio Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.